South Australian researchers working with Oracle Cloud technology and vaccine technology developed by local company Vaxine Pty Ltd are testing a vaccine candidate against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic.
The team is headed by Nikolai Petrovsky, Flinders University Professor and Research Director at Vaxine.
His team has tapped Oracle for technical collaboration, access to an expanded research community, and cloud infrastructure that helped enable the rapid design of the novel COVID-19 vaccine candidate.
“The vaccine has progressed into animal testing in the US and, once we confirm it is safe and effective, will then be advanced into human trials,” says Professor Petrovsky – stressing expectations shouldn’t be elevated until all testing is completed.
The latest cloud-based technology provided by Oracle enabled the team to “dramatically speed up our ability to analyse the COVID-19 virus and use this information to design the vaccine candidate”.
“As soon as the genomic sequence of COVID-19 became available in January, we immediately used this, combined with our previous experience in developing a SARS coronavirus vaccine, to characterise the key viral attachment molecule called the spike protein,” Professor Petrovsky says.
“We used computer models of the spike protein and its human receptor, ACE2, to identify how the virus was infecting human cells, and then were able to design a vaccine to block this process,” he says.
Flinders University Associate Professor Dimitar Sajkov, a respiratory physician in South Australia, has been involved in conducting previous human trials of the team’s pandemic vaccines and hopes to similarly lead clinical trials of this new COVID-19 vaccine candidate.
“The team has exploited the very latest technologies, including AI, advanced manufacturing and Cloud computing to accelerate vaccine design, shaving years off normal development timeframes,” Professor Sajkov says.
“We achieved great results with Vaxine’s swine flu vaccine developed during the 2009 swine flu pandemic, where we commenced clinical trials of a vaccine within 3 months of discovery of the virus. We hope to achieve similar results with their COVID-19 vaccine candidate when it is ready for human testing,” he says.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- G20 leaders pledge to fund fair distribution of COVID-19 vaccines - draft statementon November 21, 2020 at 5:32 pm
Leaders of the world's 20 biggest economies on Sunday will pledge to pay for a fair distribution of COVID-19 vaccines, drugs and tests around the world so that poorer countries are not left out, and ...
- Moderna to charge $25-$37 for COVID-19 vaccine: CEO tells paperon November 21, 2020 at 3:19 pm
Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag ...
- What does emergency use of a COVID-19 vaccine mean?on November 21, 2020 at 12:37 pm
Normally, the process to approve a new vaccine can take about a decade. But the government is using methods to speed up the process for COVID-19 vaccines.
- Houston hospitals preparing for COVID-19 vaccine deliveryon November 21, 2020 at 8:51 am
After months of anticipation about how fast a safe and effective COVID-19 vaccine could be produced, select Houston-area hospitals are scrambling to prepare for shipments of the first one, likely in ...
- A childhood vaccine available since 1979 has been linked to less severe COVID-19 but smoking cigarettes raises riskon November 21, 2020 at 5:48 am
The MMR vaccine could lessen COVID-19 severity, but cigarette smoke weakens airways and could make people more vulnerable to the coronavirus.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Experimental COVID-19 treatment given to Trump gets FDA authorizationon November 21, 2020 at 7:02 pm
The president credited the antibodies treatment with helping his recovery after he was hospitalized with the coronavirus.
- FDA grants emergency authorization of experimental antibody treatment given to Trump after COVID-19 diagnosison November 21, 2020 at 6:42 pm
The Food and Drug Administration has granted emergency authorization for the experimental antibody treatment given to President Donald Trump shortly after he was diagnosed with COVID-19, giving ...
- Covid-19 Treatment Developer AbCellera Biologics Files for IPOon November 20, 2020 at 5:23 pm
Canadian antibody-drug discovery platform AbCellera Biologics Inc. filed for an initial public offering, detailing plans for an antibody treatment for Covid-19 that it’s developing with Eli Lilly & Co ...
- The W.H.O. rejects the antiviral drug remdesivir as a Covid-19 treatment.on November 20, 2020 at 1:23 pm
The World Health Organization on Thursday recommended against using the antiviral remdesivir, a drug that had generated intense interest as a treatment for Covid-19. An expert panel “concluded that ...
- Meat Giant JBS Cuts Health Insurance Costs For Workers’ Covid-19 Treatmenton November 20, 2020 at 5:01 am
The U.S. division of the world’s largest meatpacker is eliminating the amount its workers have to pay out of pocket for care if they’ve contracted Covid-19.